期刊文献+

心身俱治是治疗勃起功能障碍的关键 被引量:18

Psychosomatic treatment:A key to the improvement of erectile dysfunction
下载PDF
导出
摘要 勃起功能障碍(ED)被公认为是一种极具代表性的心身疾病。社会心理因素在ED的发病过程中起到了关键性作用。ED对患者及其伴侣的社会心理健康以及人际关系也会产生重大影响。治疗上既包括性心理治疗,又需要适当的药物等治疗,"心身同治"是其治疗的核心。而随着健康医学模式的发展,ED的治疗目标也随之发生了巨大变革,不再单单追求阴茎勃起的硬度和维持时间,更为注重重建患者和伴侣之间自然和睦的性生活以及亲密无间的伴侣关系。新型5型磷酸二酯酶抑制剂他达拉非可有效提高各种病因和程度的ED患者勃起功能,同时明显降低患者的性时间顾虑,并很好地满足了患者及其伴侣的治疗预期,使患者及其伴侣回归正常、自然的性生活,给患者和伴侣带来巨大的社会心理收益。 Erectile dysfunction(ED) has been widely accepted as a typical psychosomatic disorder.Psychosocial factors play a critical role in the pathogenesis of ED.In turn,ED also has a substantial effect on psychosocial health and interpersonal relationship between ED patients and their partners.It is rational that psychosomatic treatment is the key to the treatment of ED,including both psychosexual counseling and appropriate medical intervention.The evolution of human health mode has revolutionized the goal of ED management,focusing on the successful restoration of natural harmonious sexual life and intimate relationship between the patients and their partners,rather than the physiological outcomes of erection hardness and duration of maintenance.Tadalafil,a novel phosphodiesterase type 5(PDE5) inhibitory agent effective for ED of any etiology and severity,can significantly decrease the time concerns of the patients,greatly satisfy the treatment expectations of both the patients and their partners,restore the normal and natural sexual life,and improve the patients' psychosexual health.
作者 范宇
出处 《中华男科学杂志》 CAS CSCD 北大核心 2011年第9期859-863,共5页 National Journal of Andrology
关键词 勃起功能障碍 他达拉非 心身疾病 性心理治疗 人际关系 erectile dysfunction tadalafil psychosomatic disorder psychosexual treatment interpersonal relationship
  • 相关文献

参考文献35

  • 1Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int, 1999, 84(1) : 50-56.
  • 2Rosen RC. Psychogenic erectile dysfunction: Classification and management. Urol Clin North Am, 2001, 28 (2) : 269-278.
  • 3Althof SE. Quality of life and erectile dysfunction. Urology, 2002, 59(6) : 803-810.
  • 4Hartmann U. Aspects of psychosomatic medicine and current treat- ment options in male sexual dysfunction. MMW Fortschr Med, 2009, 151(36) : 34-37.
  • 5Montorsi F, Briganti A, Salonia A, et al. The use of phosphodi- esterase type 5 inhibitors for erectile dysfunction. Curr Opin Urol, 2004, 14(6) : 357-359.
  • 6Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med, 2010, 7 ( 1 Pt 2) : 524-540.
  • 7Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: An update. BJU Int, 2004, 93(9) : 1276-1281.
  • 8Hatzichristou D, Haro JM, Martin-Morales A, et al. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: Results from the Erectile Dysfunction Obser- vational Study. Int J Clin Pratt, 2007, 61(11) : 1850-1862.
  • 9Perimenis P, Roumeguere T, Heidler H, et al. Evaluation of pa- tient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: The DETECT study. J Sex Med, 2009, 6(1): 257-267.
  • 10Althof S. When an erection alone is not enough : Biopsychosocial obstacles to lovemaking. Int J Impot Res, 2002, 14 ( suppl 1 ) :S99-104.

二级参考文献15

  • 1Aytac IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br J Urol Int, 1999, 84 (1) : 50-56.
  • 2NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA, 1993, 270 (1) : 83-90.
  • 3Rosen RC, Fisher WA, Eardley I, et al. The multinational mens attitudes to life events and sexuality (MALES) study : Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin, 2004, 20 (5) : 607-617.
  • 4Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: Results of the -Cologne Male Survey : Int J Impot Res, 2000, 12(6) : 305-311.
  • 5Hellstrom WJ, Kendirci M. Type 5 phosphodiesterase inhibitors : Curing erectile dysfunction. Eur Urol, 2006, 49 ( 6 ) : 942-945.
  • 6Carson CC, Rajfer J, Eardley I, et al. The efficacy and safety of tadalafil: An update. BJU Int, 2004, 93 (9) : 1276-1281.
  • 7Montorsi F, Briganti A, Salonia A, et al. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? Eur Urol, 2006, 49 (6) : 979-986.
  • 8Sommer F, Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol, 2005, 23(6) : 385-392.
  • 9Caretta N, Palego P, Ferlin A, et al. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: Role of tadalafil. Eur Urol, 2005, 48(2) : 326-331.
  • 10Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction. Endocrinol Metab Clin North Am, 2007, 36(2) : 465- 479.

共引文献17

同被引文献166

引证文献18

二级引证文献113

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部